Mayo Clinic Q & amp;A podcast: Mayo Clinic experts discuss new Alzheimer's treatment option

Last week, the Food and Drug Administration approved aducanumab to treat Alzheimer's disease, which is a progressive brain disorder that is the most common cause of dementia.  Aducanumab targets amyloid plaques in the brain that are believed to be an essential component of Alzheimer's disease. But what does the approval of a new Alzheimer's drug [...]
Source: News from Mayo Clinic - Category: Databases & Libraries Source Type: news